Nanocarriers can be functionalized with ligands or antibodies that specifically bind to receptors overexpressed on cancer cells. This targeted drug delivery method ensures that the nanocarriers are preferentially taken up by cancerous cells. Once inside the cells, the nanocarriers release their therapeutic payload, which can kill the cancer cells or inhibit their growth.
